An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes.
An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes. The action on Lynparza (olaparib) was in conjunction with approval of BRACAnalysis CDx, a companion diagnostic for detection of BRCA mutations (gBRCAm) in patients with ovarian cancer.
Lynparza’s efficacy was studied in 137 women with gBRCAm-associated ovarian cancer, based on measurement of objective response rate (ORR). The results indicated that 34% of the women experienced ORR for an average of 7.9 months.
Common side effects included indigestion, fatigue, decreased appetite, back pain, rash, and cough. Serious side effects were noted including acute myeloid leukemia, lung inflammation, and myelodysplastic syndrome.
The BRACAnalysis CDx test was reviewed under the FDA’s priority review program for devices. It had previously been marketed by the manufacturer as a laboratory-developed test for use in a single laboratory. Blood samples from participants in the study of Lynparza were used to validate detection of BRCA mutations in that population.
Of the approval, Richard Pazdur, director of the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research said, “Today’s approval constitutes the first of a new class of drugs for treating ovarian cancer. Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.”
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More